Multiple Myeloma in 2023 Ways

Multiple Myeloma in 2023 Ways: From Trials to Real Life - PMC

Median progression-free survival (PFS) and median overall survival (OS) were 4.6 and 12.4 months. Death occurred in 107 patients due to PD. The 92 varied ...

Multiple Myeloma in 2023 Ways: From Trials to Real Life - PubMed

Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better ...

Multiple Myeloma: Improved Prognosis With the Latest Treatments

In August 2023, the FDA granted accelerated approval to a second BCMA-directed bispecific antibody called elranatamab (Elrexfio™) for people ...

The latest myeloma treatment advances from ASCO 2023 - MMRF

Tecvayli. Tecvayli was the first approved off-the-shelf BCMA-directed bispecific antibody for the treatment of patients with RRMM. The approval was ...

Myeloma Today: Fall 2023

In the Fall 2023 edition, IMF Chief Medical Officer Dr. Joseph Mikhael highlights the approval of two new myeloma drugs. Those drugs, ELREXFIO™ and TALVEY™, ...

Multiple Myeloma in 2023: An Oncological Success Story - YouTube

Multiple Myeloma in 2023: An Oncological Success Story | Peter Forsberg, MD · University of Colorado | Department of Medicine · Newly Diagnosed ...

Multiple myeloma research to be presented at American Society of ...

Fred Hutch multiple myeloma expert Dr. Rahul Banerjee will present results of clinical trials aimed at reducing side effects and the time ...

Researchers discover innovative new treatment approach for ...

Although newer treatments have improved survival, multiple myeloma remains incurable, and most patients become resistant to available therapies ...

2023 Mid-Year Science Update - International Myeloma Foundation

With the introduction and assessment of new testing methodologies, as well as multiple and very active new therapies, it is crystal clear that ...

FDA Approves Two New Treatments for Heavily Pretreated Multiple ...

Rye Brook, N.Y., August 16, 2023 – The U.S. Food and Drug Administration (FDA) in August approved both talquetamab-tgvs (Talvey™) and elranatamab ...

Managing multiple myeloma in 2023 - Royal College of Pathologists

Professor Guy Pratt explores the challenges of managing multiple myeloma in today's world. Multiple myeloma has a poorly understood genetic origin.

ASCO 2023: Multiple Myeloma - American Journal of Managed Care

“Daratumumab is one of the most effective therapies for newly diagnosed or relapsed/refractory multiple myeloma. And one of the important ...

How Can Myeloma Outcomes Improve in 2024? - HealthTree

ASH 2023: How Can Relapsed/Refractory Myeloma Outcomes Improve in 2024? · A rational approach to functional high-risk patients · Considerations ...

Multiple myeloma - Diagnosis and treatment - Mayo Clinic

Radiation therapy. Radiation therapy uses powerful energy beams to kill cancer cells. The energy can come from X-rays, protons or other sources.

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI

Adding daratumumab (Darzalex) to standard VRD treatment helped people with newly diagnosed multiple myeloma live longer without their cancer ...

Functional cure and long-term survival in multiple myeloma

Today, induction with a CD38 antibody, proteasome inhibitor, immunomodulatory drug, and dexamethasone, potentially followed by autologous stem ...

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and ...

Frail patients who not candidates for transplant are treated with VRd for approximately 8–12 cycles followed by maintenance or alternatively ...

Exciting Myeloma Treatments in 2023 - YouTube

Multiple myeloma patient advocate Jack Aiello has been living with myeloma for 28 years. When he was diagnosed, he was told he would only ...

Motixafortide and Stem Cell Transplants for Multiple Myeloma - NCI

And high-dose chemotherapy and a stem cell transplant with the patient's own cells, known as an autologous transplant, is one of the main ways ...

How I treat multiple myeloma in geriatric patients - ASH Publications

Assessment of patient frailty has become more frequent and will be useful in the context of significant and continuous advances in therapy. The recent emergence ...